Why do hypertonic citrate locks lead to dialysis catheter malfunction; More than a weighty problem?

Nephrology Dialysis Transplantation

Volumn 27, Issue 7, 2012, Pages 2621-2624

  Davenport, Andrew ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BISMUTH; CITRATE TRISODIUM; CITRIC ACID; DISINFECTANT AGENT; HEPARIN; HYPERTONIC CITRATE; IMMUNOGLOBULIN A; SILVER; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; BLOOD FLOW; CATHETER CARE; CATHETER COMPLICATION; CATHETER INFECTION; CATHETER THROMBOSIS; DIALYSIS CATHETER; DIALYSIS CATHETER MULFUNCTION; EQUIPMENT DESIGN; FEMORAL VEIN; HUMAN; INFECTION RISK; MATERIAL COATING; PRIORITY JOURNAL; PROTEIN SECRETION; RISK FACTOR; RISK REDUCTION; VEIN CATHETERIZATION; VEIN THROMBOSIS;

ANTICOAGULANTS; CATHETERS, INDWELLING; CITRATES; HUMANS; PROTEINS; PULMONARY EMBOLISM; RENAL DIALYSIS;

EID: 84864401023     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs274     Document Type: Article

References (36)

1. Alwall N, Norvitt L, Steins AM. The artificial kidney VII. Clinical experiences of dialytic treatment of uraemia. Acta Med Scand 1949; 132: 157.
2. Shaldon S, Chiandussi L, Higgs B. Haemodialysis by percutaneous catheterisation of the femoral artery and vein with regional heparinisation. Lancet 1961; 2: 857-859.
3. Seldinger SI. Catheter replacement of the needle in percutaneous arteriography; a new technique. Acta Radiol 1953; 38: 368-376.
4. Shaldon S, Baillod R, Compty C et al. Eighteen months experience with a nurse patient operated chronic dialysis unit. Proc Eur Dial Transplant Assoc 1964; 1: 233-242.
5. Davenport A, Dealler SF. The epidermo-peritoneal potential in patients treated with continuous ambulatory peritoneal dialysis. Int J Artif Organs 1993; 16: 71-74.
6. Marcus RJ, Post JC, Stoodley P et al. Biofilms in nephrology. Expert Opin Biol Ther 2008; 8: 1159-1166.
7. Lok CE. Avoiding trouble down the line: the management and prevention of haemodialysis catheter-related infections. Adv Chronic Kidney Dis 2006; 13: 225-244.
8. Davenport A. Central venous catheters for haemodialysis: how to overcome the problems. Hemodial Int 2000; 4: 78-82.
9. Hemmelgarn BR, Moist LM, Lok CE et al. Prevention of dialysis catheter lumen occlusion with rt-PA versus heparin study group. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. N Engl J Med 2011; 364: 303-312.
10. Willicombe MK, Vernon K, Davenport A. Embolic complications from central venous haemodialysis catheters used with hypertonic citrate locking solution. Am J Kidney Dis 2010; 55: 348-351.
11. Kingdon EJ, Holt SG, Davar J et al. Atrial thrombus and central venous dialysis catheters. Am J Kidney Dis 2001; 38: 631-639.
12. Kundu S. Central venous disease in haemodialysis patients: prevalence, aetiology and treatment. J Vasc Access 2010; 11: 1-7.
13. Hassan A, Khalifa M, Al-Akraa M et al. Six cases of retained central venous haemodialysis access catheters. Nephrol Dial Transplant 2006; 21: 2005-2008.
14. Betjes MG. Prevention of catheter-related bloodstream infection in patients on haemodialysis. Nat Rev Nephrol 2011; 7: 257-265.
15. Battistella M, Bhola C, Lok CE. Long-term follow-up of the hemodialysis infection prevention with polysporin ointment (HIPPO) study: a quality improvement report. Am J Kidney Dis 2011; 57: 432-441.
16. Schindler R, Heemann U, Haug U et al. Bismuth coating of nontunneled haemodialysis catheters reduces bacterial colonization: a randomized controlled trial. Nephrol Dial Transplant 2010; 25: 2651-2656.
17. Maki DG, Ash SR, Winger RK et al. AZEPTIC Trial Investigators. A novel antimicrobial and antithrombotic lock solution for haemodialysis catheters: a multi-centre, controlled, randomized trial. Crit Care Med 2011; 39: 613-620.
18. Moran J, Sun S, Khababa I et al. A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance haemodialysis patients. Am J Kidney Dis 2012; 59: 102-107.
19. Jones SM, Ravani P, Hemmelgarn BR et al. Morphometric and biological characterization of biofilm in tunnelled haemodialysis catheters. Am J Kidney Dis 2011; 57: 449-455.
20. Schilcher G, Scharnagl H, Horina J et al. Trisodium citrate induced protein precipitation in haemodialysis catheters might cause pulmonary embolism. Nephrol Dial Transplant 2012; 27: 2953-2957.
21. Davenport A, Tolwani A. Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit. Clin Kidney J 2009; 2: 439-447.
22. Power A, Duncan N, Singh SK et al. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single-center randomized controlled trial. Am J Kidney Dis 2009; 53: 1034-1041.
23. Weijmer MC, van den Dorpel MA, Van de Ven PJ et al. CITRATE study group: Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in haemodialysis patients. J Am Soc Nephrol 2005; 16: 2769-2777.
24. Bosma JW, Siegert CE, Peerbooms PG et al. Reduction of biofilm formation with trisodium citrate in haemodialysis catheters: a randomized controlled trial. Nephrol Dial Transplant 2010; 25: 1213-1217.
25. Hermite L, Quenot JP, Nadji A et al. Sodium citrate versus saline catheter locks for non-tunnelled haemodialysis central venous catheters in critically ill adults: a randomized controlled trial. Intensive Care Med 2012; 38: 279-285.
26. Venditto M, du Montcel ST, Robert J et al. Effect of catheter-lock solutions on catheter-related infection and inflammatory syndrome in hemodialysis patients: heparin versus citrate 46% versus heparin/gentamicin. Blood Purif 2010; 29: 268-273.
27. Winnett G, Nolan J, Miller M et al. Trisodium citrate 46.7% selectively and safely reduces staphylococcal catheter-related bacteraemia. Nephrol Dial Transplant 2008; 23: 3592-3598.
28. Meeus G, Kuypers DR, Claes K et al. A prospective, randomized, double-blind crossover study on the use of 5% citrate lock versus 10% citrate lock in permanent haemodialysis catheters. Blood Purif 2005; 23: 101-105.
29. Grudzinski L, Quinan P, Kwok S et al. Sodium citrate 4% locking solution for central venous dialysis catheters-an effective, more cost-efficient alternative to heparin. Nephrol Dial Transplant 2007; 22: 471-476.
30. Lok CE, Appleton D, Bhola C et al. Trisodium citrate 4%-an alternative to heparin capping of haemodialysis catheters. Nephrol Dial Transplant 2007; 22: 477-483.
31. Betjes MG, van Agteren M. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrol Dial Transplant 2004; 19: 1546-1551.
32. Filiopoulos V, Hadjiyannakos D, Koutis I et al. Approaches to prolong the use of uncuffed haemodialysis catheters: results of a randomized trial. Am J Nephrol 2011; 33: 260-268.
33. Allon M. Prophylaxis against dialysis catheter-related bacteremia with a novel antimicrobial lock solution. Clin Infect Dis 2003; 36: 1539-1544.
34. Dogra GK, Herson H, Hutchison B et al. Prevention of tunneled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: a randomized controlled study. J Am Soc Nephrol 2002; 13: 2133-2139.
35. Uday S, Manoharan A, Yee J et al. Comparison of low-dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter-related bacteraemia. Am J Kidney Dis 2006; 48: 596-605.
36. Parikh S, Nijmeh R, Van Cleef S et al. Catheter outcomes in the short-term inpatient setting: a controlled quality improvement study comparing citrate and heparin lock. Semin Dial 2011; doi: 10.1111/j.1525-139X.2011.00966.